Unveiling the Potential Drug Target and Biomarker INTS6 (DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 26)

Target Name: INTS6

NCBI ID: G26512

INTS6

Unveiling the Potential Drug Target and Biomarker INTS6 (DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 26)

Introduction

INTS6 (DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26) is a protein that has been identified as a potential drug target and biomarker. This protein is derived from the Mycobacterium tuberculosis (M. tuberculosis), which is a leading cause of tuberculosis (TB) worldwide. INTS6 has been shown to have unique structural features that make it an attractive target for drug development. In this article, we will explore the potential drug target and biomarker properties of INTS6 and its potential in the development of new TB treatments.

Potential Drug Target and Biomarker Properties of INTS6

INTS6 is a 26-kDa protein that contains a unique N-terminus that consists of a long coiled region and a short linear region. The coiled region of INTS6 contains a conserved core that is involved in protein-protein interactions and may serve as a potential binding site for small molecules. The linear region of INTS6 contains several potential binding sites that may interact with other proteins.

The unique structural features of INTS6 make it an attractive target for drug development due to its potential to modulate the activity of various cellular processes. One of the potential drug targets of INTS6 is the inhibition of the translation of foreign DNA into M. tuberculosis. This process is critical for the growth and survival of M. tuberculosis, and inhibition of this process could be a potential method of targeting the disease.

Another potential drug target of INTS6 is the inhibition of the synthesis of M. tuberculosis hallmark protein, which is involved in the formation of M. tuberculosis's hallmark filaments. This protein is critical for the structural integrity of M. tuberculosis and the formation of new hallows , which are the primary cause of the disease. Therefore, inhibition of the synthesis of this protein could be a potential method of targeting the disease.

In addition to its potential drug target properties, INTS6 has also been shown to have potential biomarker properties. The expression of INTS6 has been shown to be regulated by various factors, including growth conditions, such as temperature and pH. This suggests that INTS6 may be a useful biomarker for the diagnosis and treatment of TB.

Expression and Purification of INTS6

The expression and purification of INTS6 have been shown to be possible. The Mycobacterium tuberculosis genome has been used to generate plasmids that contain the coding region for INTS6. The plasmids have been linearized by digesting the plasmid with restriction enzymes and then introduced into M. tuberculosis cells. The resulting cells have been grown in vitro and the protein has been purified using various techniques, such as affinity chromatography.

The purified INTS6 protein has been shown to have unique functional properties, including a high stability in the presence of various mutations and mutations, such as tryptophan or glutamic acid substitutions. This suggests that INTS6 may be a stable protein that can be used as a potential drug or biomarker.

Conclusion

INTS6 (DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26) has unique structural features that make it an attractive target for drug development. The potential drug targets of INTS6 include the inhibition of the translation of foreign DNA into M. tuberculosis and the inhibition of the synthesis of M. tuberculosis hallmark protein. In addition, INTS6 has also been shown to have potential biomarker properties, which may be useful for the diagnosis and treatment of TB. The expression and purification of INTS6 have been shown to be possible, and further studies are needed to determine its potential as a drug or biomarker.

Protein Name: Integrator Complex Subunit 6

Functions: Component of the Integrator (INT) complex, a complex involved in the small nuclear RNAs (snRNA) U1 and U2 transcription and in their 3'-box-dependent processing. The Integrator complex is associated with the C-terminal domain (CTD) of RNA polymerase II largest subunit (POLR2A) and is recruited to the U1 and U2 snRNAs genes (Probable). Mediates recruitment of cytoplasmic dynein to the nuclear envelope, probably as component of the INT complex (PubMed:23904267). May have a tumor suppressor role; an ectopic expression suppressing tumor cell growth (PubMed:15254679, PubMed:16239144)

The "INTS6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INTS6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets